贝达药业,300558,收入构成,报告日期,2020-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药制造,187027,13890,173137,92.57%,100% 贝达药业,300558,收入构成,报告日期,2019-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药制造,155392,10523,144870,93.23%,100% 贝达药业,300558,收入构成,报告日期,2018-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药制造,122417,6899,115518,94.36%,100% 贝达药业,300558,收入构成,报告日期,2018-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 盐酸埃克替尼,58134,2611,55522,95.51%,100% 贝达药业,300558,收入构成,报告日期,2017-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药制造,102636,4370,98266,95.74%,100% 贝达药业,300558,收入构成,报告日期,2016-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 医药制造,103506,3283,100223,96.83%,100% 贝达药业,300558,收入构成,报告日期,2016-06-30, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),12,-- ,12,--,0.02% 埃克替尼,51846,1547,50299,97.02%,99.98% 贝达药业,300558,收入构成,报告日期,2015-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),7,-- ,7,--,0.01% 技术服务,170,-- ,170,--,0.19% 烧伤止痛膏,2,1,1,65.71%,0% 埃克替尼,91288,2794,88494,96.94%,99.8% 贝达药业,300558,收入构成,报告日期,2014-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),8,-- ,8,--,0.01% 谷维素双维B片,59,17,41,70.39%,0.06% 烧伤止痛膏,77,58,20,25.55%,0.03% 埃克替尼,70299,2366,67933,96.63%,99.9% 贝达药业,300558,收入构成,报告日期,2013-12-31, 按行业,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),6,-- ,6,--,0.01% 技术服务,11,-- ,11,--,0.02% 谷维素双维B片,356,89,267,75%,0.58% 烧伤止痛膏,216,175,41,18.95%,0.09% 埃克替尼,47481,1873,45607,96.05%,99.29%